Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: Results of a phase II study

Cancer Journal

Volumn 6, Issue 3, 2000, Pages 146-150

  Longo, Dan L ^a,e   Duffey, Patricia L ^a   Gribben, John G ^b   Jaffe, Elaine S ^c   Curti, Brendan D ^a   Gause, Barry L ^a   Janik, John E ^a   Braman, Virginia M ^d   Esseltine, Dixie ^d   Wilson, Wyndham H ^c   Kaufman, Dwight ^c   Wittes, Robert E ^c   Nadler, Lee M ^b   Urba, Walter J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d IMMUNOGEN INC   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IMMUNOTOXIN; METHOTREXATE; PREDNISONE; RICIN; VINCRISTINE SULFATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; LYMPHOMA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; LYMPHOMA; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; LYMPHOMA, SMALL LYMPHOCYTIC; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; RICIN; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0008744532     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 1984;311:1471-1475.
2. Lambert JM, Goldmacher VS, Collinson AR et al. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res 1991;51:6236-6242.
3. Grossbard ML, Freedman AS, Ritz J et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 1992;79:576-585.
4. Grossbard ML, Gribben JG, Freedman AS et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993;81:2263-2271.
5. Longo DL, DeVita VT Jr, Duffey PL et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of patients with diffuse aggressive histology lymphoma. J Clin Oncol 1991;9:25-38.
6. Gribben JG, Freedman AS, Woo SD et al. All advanced-stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991;78:3275-3284.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
8. McLaughlin P, Hagemeister FB, Romaguera JE et al. Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996;14:1262-1268.
9. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276.
10. O'Connor R, Liu C, Ferris CA et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 1995;86:4286-4294.